International Journal of Heart Failure最新文献

{"title":"Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure.","authors":"Barry Greenberg","doi":"10.36628/ijhf.2020.0002","DOIUrl":"https://doi.org/10.36628/ijhf.2020.0002","url":null,"abstract":"<p><p>Recognition that neurohormonal activation plays a central role in the pathogenesis of heart failure (HF) led to the development of angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers, mineralocorticoid receptor antagonists and beta blockers. While there has been substantial success with these neurohormonal blocking drugs in patients with HF with reduced ejection fraction (HFrEF), persistently high rates of morbidity and mortality in this population underscore the need for more effective therapies. As part of the systemic neurohormonal activation that takes place in patients with HF, systems that counteract the adverse effect of the renin angiotensin aldosterone system (RAAS) and sympathetic nervous system (SNS) are also activated. Evidence that neprilysin metabolizes many of the effector molecules produced by these counter-regulatory systems raised the possibility that inhibition of this enzyme might be beneficial. However, since angiotensin II is a substrate of neprilysin, inhibition of the enzyme alone would increase levels of this peptide. Thus, treatment strategies that combine RAAS blockade with neprilysin inhibition were sought. Recent large scale randomized clinical trials (RCTs) have provided compelling evidence that sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to an ACEI in reducing mortality and HF hospitalization and in improving quality of life in patients with stage C HFrEF. In these trials, sacubitril-valsartan was found to be safe and well tolerated. This review presents the rationale for using ARNIs, describes the RCTs showing their efficacy, summarizes updated recommendations from recent guidelines, and provides practical points about ARNI initiation and up-titration.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 2","pages":"73-90"},"PeriodicalIF":0.0,"publicationDate":"2020-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/bf/ijhf-2-73.PMC9536660.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diastolic Function Assessment in Atrial Fibrillation Conundrum.","authors":"Grace Casaclang-Verzosa","doi":"10.36628/ijhf.2020.0012","DOIUrl":"10.36628/ijhf.2020.0012","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 2","pages":"115-117"},"PeriodicalIF":0.0,"publicationDate":"2020-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/72/ijhf-2-115.PMC9536663.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of QRS Duration among Patients with Cardiogenic Shock Complicating Acute Heart Failure: Data from the Korean Acute Heart Failure (KorAHF) Registry.","authors":"Jung Ae Hong,&nbsp;Min-Seok Kim,&nbsp;Hanbit Park,&nbsp;Sang Eun Lee,&nbsp;Hae-Young Lee,&nbsp;Hyun-Jai Cho,&nbsp;Jin Oh Choi,&nbsp;Eun-Seok Jeon,&nbsp;Kyung-Kuk Hwang,&nbsp;Shung Chull Chae,&nbsp;Sang Hong Baek,&nbsp;Seok-Min Kang,&nbsp;Dong-Ju Choi,&nbsp;Byung-Su Yoo,&nbsp;Kye Hun Kim,&nbsp;Myeong-Chan Cho,&nbsp;Jae-Joong Kim,&nbsp;Byung-Hee Oh","doi":"10.36628/ijhf.2019.0016","DOIUrl":"https://doi.org/10.36628/ijhf.2019.0016","url":null,"abstract":"<p><strong>Background and objectives: </strong>Prolonged QRS duration is associated with poor outcomes in patients with chronic heart failure (HF). However, the prognostic value of QRS duration in patients with cardiogenic shock complicating acute HF remains unknown. We evaluated the hypothesis that prolonged QRS duration may be associated with short-term mortality among acute HF patients with cardiogenic shock (CS).</p><p><strong>Methods: </strong>From March 2011 through December 2013, a total of 5,625 acute HF patients were consecutively enrolled in ten tertiary university hospitals. Among them, we analyzed patients who presented with CS. Patients were divided into three groups by QRS duration cutoff values of 130 and 150 ms. The primary endpoint was 30-day in-hospital mortality.</p><p><strong>Results: </strong>Two hundred eleven patients presented with CS at admission and those with available electrocardiograms were included in this analysis. There were 35 patients with QRS durations of 150 ms or above, 30 patients with QRS durations between 130 ms and 150 ms, and 146 patients with QRS durations below 130 ms. The 30-day all cause in-hospital mortality rates were 43.7%, 33.1%, and 24.9%, respectively. After multivariate adjustment, severe prolonged QRS duration was a significant prognostic factor for 30-day in-hospital mortality (hazard ratio, 1.909; 95% confidence interval, 1.024-3.558; p=0.042).</p><p><strong>Conclusions: </strong>Prolonged QRS duration was associated with a higher risk of 30-day in-hospital mortality among patients with acute HF who presented with CS.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT01389843.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 2","pages":"121-130"},"PeriodicalIF":0.0,"publicationDate":"2020-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/8b/ijhf-2-121.PMC9536664.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Left Ventricular Diastolic Function and Its Association with the Left Atrial Pressure in Patients with Atrial Fibrillation.","authors":"Mi-Na Kim,&nbsp;Seong-Mi Park,&nbsp;Hee-Dong Kim,&nbsp;Dong-Hyuk Cho,&nbsp;Jaemin Shim,&nbsp;Jong-Il Choi,&nbsp;Young Hoon Kim,&nbsp;Wan Joo Shim","doi":"10.36628/ijhf.2020.0003","DOIUrl":"https://doi.org/10.36628/ijhf.2020.0003","url":null,"abstract":"Background and Objectives The evaluation of left ventricular (LV) diastolic function in patients with atrial fibrillation (AF) is challenging. This study aimed to investigate the efficacy of the diagnostic algorithm for LV diastolic dysfunction (LVDD) in the current guidelines and to evaluate the association between increased left atrial pressure (LAP) and LV diastolic parameters. Methods One hundred and twenty-four patients with non-valvular AF and a preserved LV ejection fraction who had the same rhythm status on echocardiography and LAP measurements during catheter ablation were included. LV diastolic function was classified as normal, indeterminate, or LVDD according to the recent guidelines. Increased LAP was defined as mean LAP (mLAP) ≥15 mmHg. Results The mLAP was not different among the normal, indeterminate, and LVDD groups. However, the prevalence of increased LAP was higher in the LVDD group. Among the LV diastolic parameters, only medial E/e′ was independently associated with mLAP in the whole study population. In patients with persistent AF (PeAF), E/e′ and e′ were significantly associated with mLAP, whereas in paroxysmal AF (PAF), mLAP was not associated with the LV diastolic parameters but with left atrial conduit function. Conclusions In general, increased LAP is known to be closely related with LVDD. However, the algorithm for LVDD from recent guidelines does not reflect well the increased LAP in AF patients. The diastolic parameters may aid in estimating the increased LAP in PeAF but may only have limited value for assessing increased LAP in PAF.","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"55-65"},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/0d/ijhf-2-55.PMC9536730.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanical Circulatory Support for Acute Heart Failure Complicated by Cardiogenic Shock.","authors":"Min Suk Choi, Hunbo Shim, Yang Hyun Cho","doi":"10.36628/ijhf.2019.0015","DOIUrl":"10.36628/ijhf.2019.0015","url":null,"abstract":"<p><p>Acute heart failure is a potentially life-threatening condition that can lead to cardiogenic shock, which is associated with hypotension and organ failure. Although there have been many studies on the treatment for cardiogenic shock, early mortality remains high at 40-50%. No new medicines for cardiogenic shock have been developed. Recently, there has been a gradual decline in the use of the intra-aortic balloon pump mainly due to a lack of adequate hemodynamic support. Extracorporeal membrane oxygenation and the percutaneous ventricular assist device have become more widely used in recent years. A thorough understanding of the mechanisms of such mechanical support devices and their hemodynamic effects, components of the devices, implantation technique, management, criteria for indications or contraindications of use, and clinical outcomes as well as multidisciplinary decision making may improve the outcomes in patients experiencing cardiogenic shock.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"23-44"},"PeriodicalIF":0.0,"publicationDate":"2020-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/35/f1/ijhf-2-23.PMC9536734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volume Status, a Novel Marker of Contrast Induced Acute Kidney Injury in Acute Heart Failure Undergoing Coronary Angiography?","authors":"Sung Woo Lee","doi":"10.36628/ijhf.2019.0018","DOIUrl":"10.36628/ijhf.2019.0018","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"69-71"},"PeriodicalIF":0.0,"publicationDate":"2020-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/f1/ijhf-2-69.PMC9536735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure and Body Habitus: What Would Be the Confounding Factors of Outcome Prediction in Obese Patients with Heart Failure?","authors":"Jae Yeong Cho, Kye Hun Kim","doi":"10.36628/ijhf.2019.0017","DOIUrl":"10.36628/ijhf.2019.0017","url":null,"abstract":"","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"66-68"},"PeriodicalIF":0.0,"publicationDate":"2020-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/48/ijhf-2-66.PMC9536729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials.","authors":"Eri Toda Kato,&nbsp;Takeshi Kimura","doi":"10.36628/ijhf.2019.0013","DOIUrl":"https://doi.org/10.36628/ijhf.2019.0013","url":null,"abstract":"<p><p>Heart failure (HF) and type 2 diabetes mellitus (T2DM) are progressive chronic diseases that increase the risk of mortality and have worse outcomes when they coexist. There has been a paucity of data on effective therapeutic measures that reduce the risk of HF in patients with T2DM. However, the issuance of the Food and Drug Administration guidance in 2008 generated data on several antihyperglycemic agents that show cardiovascular (CV) benefits beyond glucose lowering. Among them, sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a class of drug with proven robust benefits in modulating HF and kidney diseases in patients with T2DM. In this article, we reviewed the epidemiology, pathophysiology, prognosis, lifestyle management, and therapeutic options, especially SGLT2 inhibitors, for HF and T2DM.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"12-22"},"PeriodicalIF":0.0,"publicationDate":"2020-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/f9/ijhf-2-12.PMC9536731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Body Mass Index on the Prognostic Value of N-Terminal proB-Type Natriuretic Peptide in Patients with Heart Failure: an Analysis from the Korean Heart Failure (KorHF) Registry.","authors":"Hack-Lyoung Kim,&nbsp;Myung-A Kim,&nbsp;Sohee Oh,&nbsp;Dong-Ju Choi,&nbsp;Seongwoo Han,&nbsp;Eun-Seok Jeon,&nbsp;Myeong-Chan Cho,&nbsp;Jae-Joong Kim,&nbsp;Byung-Su Yoo,&nbsp;Mi-Seung Shin,&nbsp;Seok-Min Kang,&nbsp;Shung Chull Chae,&nbsp;Kyu-Hyung Ryu","doi":"10.36628/ijhf.2019.0005","DOIUrl":"https://doi.org/10.36628/ijhf.2019.0005","url":null,"abstract":"<p><strong>Background and objectives: </strong>Although an inverse correlation between the level of amino (N)-terminal pro-brain natriuretic peptide (NT-proBNP) and body mass index (BMI) has been reported, the impact of BMI on the prognostic value of NT-proBNP has not been well addressed.</p><p><strong>Methods: </strong>A total of 1,877 patients (67-year-old and 49.9% females) hospitalized for acute heart failure (HF) with documented NT-proBNP levels at baseline were included. Patients were classified into 2 groups by BMI (nonobese: BMI<23 kg/m² and overweight or obese: BMI≥23 kg/m²). Clinical events during the follow-up including all-cause mortality and HF readmission were assessed.</p><p><strong>Results: </strong>During the median follow-up of 828 days (interquartile range, 111-1,514 days), there were 595 cases of total mortality (31.7%), 600 cases of HF readmission (32.0%), and 934 cases of composite events (49.8%). In unadjusted analyses, higher NT-proBNP level was associated with all-cause mortality and composite events (all-cause mortality and HF readmission) in both patients with BMI<23 kg/m² and those with BMI≥23 kg/m². In adjusted analyses controlling for potential confounders, however, a higher NT-proBNP level was associated with all-cause mortality and composite events in patients with BMI<23 kg/m², but not in those with BMI≥23 kg/m².</p><p><strong>Conclusions: </strong>The prognostic value of NT-proBNP was more significant in nonobese patients than in overweight and obese patients in this HF population. BMI should be considered when NT-proBNP is used for risk estimation in HF patients.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"45-54"},"PeriodicalIF":0.0,"publicationDate":"2019-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/17/ijhf-2-45.PMC9536733.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Heart Failure Treatment by Heart Rate Reduction.","authors":"Michael Böhm,&nbsp;Yvonne Bewarder,&nbsp;Ingrid Kindermann,&nbsp;Jonathan Slawik,&nbsp;Jan Wintrich,&nbsp;Christian Werner","doi":"10.36628/ijhf.2019.0009","DOIUrl":"https://doi.org/10.36628/ijhf.2019.0009","url":null,"abstract":"<p><p>Heart failure (HF) treatment should be optimized in addition to guideline-directed and recommended drugs to achieve an appropriate heart rate (i.e. 50-60 bpm) by ivabradine in patients with a heart rate >70 bpm in sinus rhythm and with an ejection fraction ≤35%. Heart rate reduction was to reduce cardiovascular death and HF hospitalization dependent on baseline resting heart rate. In particular in patients at a heart rate >75 bpm, a reduction in cardiovascular death, all-cause death, HF death, HF hospitalization and all-cause hospitalization has been observed. The optimal heart rate achieved appears to be between 50-60 bpm, if well tolerated as in these patients the lowest event rate is observed on treatment. Heart rate reduction is, therefore, a treatable risk factor in chronic HF. Observational studies support the concept that it is a risk indicator in other cardiovascular and non-cardiovascular conditions. Whether heart rate reduction is also modifying risk in other conditions than chronic HF should be explored in prospective clinical trials.</p>","PeriodicalId":14058,"journal":{"name":"International Journal of Heart Failure","volume":"2 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2019-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/39/ijhf-2-1.PMC9536732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}